Brokerages Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target at $13.79

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been given an average rating of “Moderate Buy” by the seven analysts that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $13.79.

MRNS has been the subject of several research reports. StockNews.com lowered shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Truist Financial reiterated a “buy” rating and issued a $10.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Royal Bank of Canada reissued a “sector perform” rating and issued a $3.00 price target (down from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday, April 15th. Oppenheimer reissued a “market perform” rating and issued a $9.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th. Finally, Robert W. Baird reaffirmed a “neutral” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. lifted its position in Marinus Pharmaceuticals by 383.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 5,003 shares during the period. SG Americas Securities LLC bought a new position in Marinus Pharmaceuticals in the fourth quarter worth approximately $134,000. Sherbrooke Park Advisers LLC bought a new position in Marinus Pharmaceuticals in the third quarter worth approximately $141,000. Acuta Capital Partners LLC bought a new position in Marinus Pharmaceuticals in the third quarter worth approximately $157,000. Finally, Jacobs Levy Equity Management Inc. bought a new position in Marinus Pharmaceuticals in the first quarter worth approximately $384,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Trading Down 4.9 %

Shares of MRNS stock opened at $1.17 on Friday. The company has a 50 day moving average of $1.41 and a 200-day moving average of $6.46. The company has a quick ratio of 2.93, a current ratio of 3.07 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $11.26. The firm has a market cap of $64.27 million, a P/E ratio of -0.44 and a beta of 1.11.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, meeting the consensus estimate of ($0.68). Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. The firm had revenue of $7.68 million during the quarter, compared to the consensus estimate of $8.61 million. Sell-side analysts anticipate that Marinus Pharmaceuticals will post -1.87 earnings per share for the current year.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.